Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.

Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance.Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resist...

Descripción completa

Detalles Bibliográficos
Publicado en:Annals of Internal Medicine Vol. 144; no. 2; pp. 94 - 101
Autores principales: De Francesco V, Margiotta M, Zullo A, Hassan C, Troiani L, Burattini O, Stella F, Di Leo A, Russo F, Marangi S, Monno R, Stoppino V, Morini S, Panella C, Ierardi E, De Francesco, Vincenzo, Margiotta, Marcella, Zullo, Angelo, Hassan, Cesare, Troiani, Laura
Formato: clinical trial research tables/charts Journal Article
Publicado: American College of Physicians 1/17/2006
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106451450&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 106451450
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00034819
        AIM
      jtl: Annals of Internal Medicine
      issn: 00034819
      maglogo: N
    pubinfo:
      dt: 1/17/2006
      vid: 144
      iid: 2
      pid: 1652
      pub: American College of Physicians
      place: Philadelphia, Pennsylvania
    artinfo:
      ui:
        106451450
        NLM16418408
        2009179012
        10.7326/0003-4819-144-2-200601170-00006
        NLM16418408
        106451450
      ppf: 94
      ppct: 7
      formats:
      tig:
        atl: Clarithromycin-resistant genotypes and eradication of Helicobacter pylori.
      aug:
        au:
          De Francesco V
          Margiotta M
          Zullo A
          Hassan C
          Troiani L
          Burattini O
          Stella F
          Di Leo A
          Russo F
          Marangi S
          Monno R
          Stoppino V
          Morini S
          Panella C
          Ierardi E
          De Francesco, Vincenzo
          Margiotta, Marcella
          Zullo, Angelo
          Hassan, Cesare
          Troiani, Laura
        affil: Ospedali Riuniti and University of Foggia, Foggia, Italy
      sug:
        subj:
          Amoxicillin Administration and Dosage
          Clarithromycin Administration and Dosage
          Drug Resistance, Microbial
          Genotype
          Helicobacter Infections Drug Therapy
          Helicobacter Pylori
          Helicobacter Pylori Drug Effects
          Omeprazole
          Chi Square Test
          Clinical Trials
          Data Analysis Software
          Drug Therapy, Combination
          Fisher's Exact Test
          Funding Source
          Helicobacter Infections Microbiology
          Hospitals
          Multivariate Analysis
          Mutation
          Random Assignment
          Secondary Analysis
          T-Tests
          Treatment Outcomes
          Human
      ab: Background: Three point mutations (A2143G, A2142G, and A2142C) have been involved in Helicobacter pylori clarithromycin resistance.Objective: To compare the eradication rates among the different point mutations and the efficacy of triple therapy and a sequential regimen according to genotypic resistance.Design: Post hoc subgroup study from a multicenter, randomized trial.Setting: Two hospitals in central and southern Italy between January and December 2001.Patients: 156 patients with H. pylori infection.Measurements: Real-time polymerase chain reaction for assessing clarithromycin resistance; histology, rapid urease test, and 13C-urea breath test at entry and after 4 to 6 weeks.Intervention: 7-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 1 g of amoxicillin) in 75 patients or a 10-day sequential regimen (20 mg of rabeprazole plus 1 g of amoxicillin for 5 days and 20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of tinidazole for the remaining 5 days) in 81 patients. All drugs were given twice daily.Results: Helicobacter pylori infection was eradicated in 11 of 23 patients (48%) with the A2143G mutation and in 14 of 15 patients (93%) with either A2142G or A2142C strains (difference, 45 percentage points [95% CI, 15 to 65 percentage points]; P = 0.004). The sequential regimen achieved a higher cure rate than triple therapy in A2143G mutate strains (difference, 49 percentage points [CI, 8 to 72 percentage points]; P = 0.024).Limitations: The post hoc substudy design may require further confirmation. Other limitations are the accessibility to the tool and the cost of investigations (70 euros per patient).Conclusions: The A2143G mutation seemed to be associated with a very low eradication rate. The sequential regimen achieved a higher cure rate than standard therapy even in patients with these strains.
      pubtype: Academic Journal
      doctype:
        clinical trial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N